Related Experiment Video

Updated: Dec 4, 2025

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

17.0K

Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement

Isabela Peixoto Biscotto1, Valéria Aparecida Costa Hong2, Rafael Loch Batista3

  • 1Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular LIM42, Disciplina de Endocrinologia, Departamento de Clínica Médica do Hospital das Clínicas da Faculdade de Medicina da Universidade São Paulo, Av. Dr. Eneas de Carvalho Aguiar, 255, Sao Paulo, SP, 05403-000, Brazil. isapbiscotto@gmail.com.

Pituitary
|October 24, 2020
PubMed

Insights

Adults with congenital growth hormone deficiency (GHD) not on GH replacement therapy (GHRT) had unfavorable body composition but similar vascular properties compared to those on GHRT. GHRT decisions for adults with GHD remain individualized.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Vascular Biology

Background:

  • Congenital growth hormone deficiency (GHD) in adults can lead to adverse metabolic and body composition changes.
  • The impact of GH replacement therapy (GHRT) on vascular properties in adults with GHD requires further investigation.

Purpose of the Study:

  • To evaluate and compare metabolic profiles and vascular properties in adult patients with congenital GHD, with and without GH replacement therapy (GHRT).

Main Methods:

  • A cross-sectional study involving 81 adult subjects: 29 GHD patients on GHRT, 20 GHD patients without GHRT, and 32 controls.
  • Assessment included anthropometric parameters, body composition (DXA), metabolic profiles, and vascular properties (carotid intima-media thickness, pulse wave velocity, flow-mediated dilation).

Main Results:

  • Patients without GHRT exhibited significantly higher waist-to-height ratio, body fat percentage, and fat mass index compared to those on GHRT.
  • Patients without GHRT showed unfavorable lipid profiles with higher triglycerides and lower HDL cholesterol than controls.
  • No significant differences in vascular properties were observed among the three groups.

Conclusions:

  • Adults with congenital GHD without GHRT present with poorer body composition but do not show differences in vascular properties compared to those receiving GHRT.
  • These findings support an individualized approach to GHRT in adults with GHD, considering metabolic and body composition outcomes.
Abstract

Keywords:
Cardiovascular riskCongenital growth hormone deficiencyGrowth hormone replacement therapyVascular system

More Related Videos

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion08:22

Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion

Published on: March 20, 2017

9.0K
Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification07:23

Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification

Published on: December 3, 2016

12.3K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
657
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
227
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
105
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.5K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
2.7K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
109